Dawn Therapeutics
Develops genetic medicine delivery platforms and a preclinical Hurler syndrome treatment for patients with serious diseases
Highlights
- New on EvolcAdded 2026-11-14
About Dawn Therapeutics
Dawn Therapeutics is a preclinical biotechnology company developing targeted delivery platforms for genetic medicines. Its platforms include stealth lentiviral vectors and targeted lipid nanoparticles; DAWN-01 is its lead programme for Hurler syndrome (MPS I).
The company is based in London and was founded in the UK in 2019. It aims to advance DAWN-01 through manufacturing and safety studies toward clinical testing, subject to funding and regulatory review.
Product: Preclinical genetic medicine delivery platforms and DAWN-01, an investigational gene therapy programme for Hurler syndrome.
Jobs at Dawn Therapeutics
Leadership
- Nagy Habib · Founder & Chief Executive OfficerSource: company website
More biotech & pharma companies
Dloc Biosystems
Organ-on-chip systems and preclinical drug-testing services for pharmaceutical and biomedical research teamsYoung companyNew on EvolcDMPK Consulting
DMPK consultancy and expert reviews for drug discovery teams and life science investors, from hit identification to Phase IINew on EvolcDnae Group Holdings
Point-of-need semiconductor DNA sequencing diagnostics for infection testing in hospital settings, developed in LondonDodrotu
Physics-based molecular discovery workflows and datasets for drug developers targeting oncology and infectious diseasesNew on EvolcDomainex
Integrated drug discovery CRO running hit identification to lead optimisation projects for life science organisationsDraig Therapeutics
Develops neuropsychiatric drug therapies for patients with depression and other brain disorders
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Hosting
- VercelHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-vercel-id
- Response headerx-vercel-id
- Response headerx-vercel-id
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.